Stock listing

NASDAQ:VANI Vivani Medical, Inc. Stock

Home listing (NASDAQ) of Vivani Medical, Inc.

Follow Vivani Medical, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:VANI

$1.14 USD +0.09 (+8.6%)

Close on Nov 20, 2026

Past year -15.6% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$1.10 – $1.16 USDNov 20, 2026
Volume
448,602 sharesNov 20, 2026
Market cap
$102.8M USDAt the close on Nov 20, 2026 · price × 90.20M shares outstanding
52-week range
$0.80 – $1.66 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$266,975 USDMedian day 177,180 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Vivani Medical, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:VANI · Home$1.14 USD+0.09 (+8.6%)448,602$1.14$1.155$1.10$1.05Close on Nov 20, 2026
Frankfurt:U5P€0.97 EUR+0.045 (+4.9%)—€0.90€0.97€0.90€0.925Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:VANI · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$1.14+0.09+8.6%$1.14$1.155$1.10448,602
$1.050.000.0%$1.02$1.08$1.02177,180
$1.05+0.03+2.9%$1.02$1.089$0.992260,144
$1.02+0.01+1.0%$1.05$1.11$1.01459,680
$1.01+0.027+2.7%$0.97$1.03$0.888367,707
$0.983-0.147-13.0%$1.12$1.12$0.801,391,414
$1.13-0.02-1.7%$1.15$1.16$1.115135,209
$1.15+0.025+2.2%$1.15$1.16$1.09170,230
$1.125+0.055+5.1%$1.09$1.14$1.08108,163
$1.07+0.03+2.9%$1.04$1.098$1.04262,143
$1.04-0.03-2.8%$1.07$1.10$1.01401,190
$1.07+0.02+1.9%$1.08$1.085$1.04180,969
$1.05-0.04-3.7%$1.09$1.13$1.04282,605
$1.090.000.0%$1.13$1.16$1.084185,517
$1.09-0.05-4.4%$1.12$1.12$1.07185,033
$1.140.000.0%$1.13$1.195$1.125190,037
$1.140.000.0%$1.12$1.16$1.07266,470
$1.14+0.01+0.9%$1.12$1.175$1.12197,521
$1.13+0.02+1.8%$1.11$1.15$1.11122,499
$1.11+0.02+1.8%$1.08$1.11$1.07585,800
$1.09-0.07-6.0%$1.121$1.135$1.065241,000
$1.16+0.04+3.6%$1.13$1.17$1.12161,200
$1.120.000.0%$1.13$1.155$1.1189,600
$1.120.000.0%$1.12$1.14$1.1080,400
$1.12-0.03-2.6%$1.15$1.165$1.10361,600
$1.15-0.01-0.9%$1.15$1.17$1.15108,400
$1.16-0.02-1.7%$1.17$1.186$1.16157,100
$1.18-0.01-0.8%$1.19$1.19$1.16269,100
$1.19-0.06-4.8%$1.22$1.23$1.19146,500
$1.25+0.02+1.6%$1.22$1.25$1.21101,900
$1.23-0.04-3.1%$1.26$1.31$1.19260,700
$1.27+0.03+2.4%$1.25$1.335$1.242272,400
$1.24+0.02+1.6%$1.24$1.26$1.22100,600
$1.22-0.01-0.8%$1.22$1.25$1.2295,200
$1.23+0.01+0.8%$1.25$1.25$1.2388,200
$1.22-0.02-1.6%$1.23$1.26$1.2263,800
$1.24+0.01+0.8%$1.24$1.27$1.24119,100
$1.23-0.02-1.6%$1.25$1.25$1.2282,900
$1.25+0.01+0.8%$1.24$1.27$1.23107,000
$1.24+0.01+0.8%$1.25$1.26$1.23128,200
$1.230.000.0%$1.23$1.24$1.2280,200
$1.23-0.04-3.1%$1.26$1.27$1.21149,100
$1.27+0.03+2.4%$1.24$1.31$1.24174,900
$1.24+0.05+4.2%$1.20$1.27$1.20131,800
$1.19-0.02-1.7%$1.22$1.229$1.17904,500
$1.21-0.01-0.8%$1.22$1.24$1.205219,800
$1.22-0.01-0.8%$1.23$1.24$1.215141,800
$1.23-0.03-2.4%$1.26$1.275$1.21208,600
$1.26-0.01-0.8%$1.26$1.284$1.24150,500
$1.27+0.02+1.6%$1.25$1.29$1.24249,300
$1.25-0.065-4.9%$1.31$1.31$1.25254,300
$1.315-0.04-3.0%$1.36$1.36$1.315282,500
$1.355-0.135-9.1%$1.50$1.50$1.34465,800
$1.49+0.10+7.2%$1.40$1.515$1.38475,100
$1.39-0.03-2.1%$1.44$1.47$1.37231,100
$1.42+0.06+4.4%$1.37$1.45$1.37140,400
$1.36-0.03-2.2%$1.36$1.388$1.35191,500
$1.39-0.03-2.1%$1.44$1.48$1.37208,200
$1.42+0.02+1.4%$1.41$1.43$1.39163,000
$1.40-0.015-1.1%$1.42$1.42$1.39586,700
$1.415-0.005-0.4%$1.43$1.45$1.37215,700
$1.42+0.04+2.9%$1.38$1.42$1.34200,718
$1.380.000.0%$1.40$1.415$1.343174,442
$1.38-0.03-2.1%$1.44$1.44$1.365104,700
$1.41+0.02+1.4%$1.36$1.423$1.36108,100

Splits

2 splits since 2020 · NASDAQ:VANI · every price before a split is adjusted for it

DayRatioWhat
1-for-3Consolidation
1-for-8Consolidation
Ticker
NASDAQ:VANI
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Vivani Medical, Inc. news

Vivani Medical, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
20 in the last 12 months · 101 in all · newest Nov 16, 2026 · oldest 2019
Decks
44 decks · latest Nov 16, 2026

Where Vivani Medical, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:VANI · Home listing · This pageNASDAQUnited StatesUSD
LS Exchange:A3DTRXLS ExchangeGermanyEUR
gettex:U5PgettexGermanyEUR
Lang & Schwarz:A3DTRXLang & SchwarzGermanyEUR
BOATS:VANIBOATSUnited StatesUSD
Dusseldorf:U5PDusseldorfGermanyEUR
Frankfurt:U5PFrankfurtGermanyEUR
Munich:U5PMunichGermanyEUR
Stuttgart:U5PStuttgartGermanyEUR
Tradegate:U5PTradegateGermanyEUR

Valuation

Price/book 7.8× against a median of 3.8×: 5th lowest of 7 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$88.24M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
7.8×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta vs S&P 500
0.93

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Vivani Medical, Inc. · NASDAQ:VANIUS$102.8MUS$88.24Mn/an/an/a7.8×n/a0.0×0.93
Nykode Therapeutics ASA · OSL:NYKDUS$107.0MUS$62.24Mn/an/an/a1.3×n/a0.0×n/a
JW (Cayman) Therapeutics Co. Ltd. · HKEX:2126US$105.3MUS$84.72Mn/a2.0×n/a1.6×−195.8%0.6×n/a
Genelux Corporation · NASDAQ:GNLXUS$104.3MUS$93.85Mn/a11,732×n/a11.4×n/a0.0×1.52
Cardiol Therapeutics Inc. Class A · TSX:CRDLUS$103.4MUS$83.06Mn/an/an/a5.4×n/a0.0×1.45
Heidelberg Pharma AG · XETR:HPHAUS$103.2MUS$81.75Mn/a8.0×n/an/a−320.9%n/an/a
Foghorn Therapeutics Inc. · NASDAQ:FHTXUS$103.1M−US$9.22M10.9×−0.1×−2.5×n/a8.4%n/a1.57
Paradigm Biopharmaceuticals Ltd. · ASX:PARUS$101.6MUS$96.33Mn/a1,816×n/a44.2×n/a2.2×n/a
Innate Pharma SA Class A · EURONEXT:IPHUS$101.5MUS$111.7Mn/a36.5×n/an/an/an/an/a
BRIM Biotechnology, Inc. · TWSE:6885US$100.3MUS$70.71Mn/a220×n/a2.1×n/a0.0×n/a
Minerva Neurosciences, Inc · NASDAQ:NERVUS$99.67MUS$22.73Mn/an/an/an/an/an/a1.68
Median of the othersUS$103.2MUS$82.41M10.9×36.5×−2.5×3.8×−195.8%0.0×1.55

Forecasts

2 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 13, 2026. Not 6ix's view and not investment advice.

Price target
3.83 USD · Analysts' mean
EPS, year to Dec 2026
-0.32 · 2 analysts

Team and board

Officers

OfficerRole
Adam MendelsohnCo-Founder & Chief Executive Officer
Anthony BaldorChief Financial Officer
Jami TaylorInvestor Relations
Don DwyerChief Business Officer
Lisa PorterChief Medical Officer
Truc LeChief Operations Officer

Board

DirectorRole
Gregg WilliamsDirector & Chairman of the Board
Aaron MendelsohnMember of the Board
Adam MendelsohnCo-Founder & Chief Executive Officer
Alexandra L. PopoffMember of the Board
August J. MorettiMember of the Board
Daniel BradburyMember of the Board

Events

QuarterResultsShare move
Q3 2026Nov 11, 2026 · After close−13.0%
Q2 2026Aug 13, 2026 · After close+4.5%
Q1 2026May 13, 2026 · After close+3.5%
Q4 2025Mar 26, 2026−9.7%
Q3 2025Nov 13, 2025 · Before open−11.4%
Q2 2025Aug 13, 2025 · After close+0.8%
Q1 2025May 12, 2025 · Before open−1.0%
Q4 2024Mar 31, 2025 · Before open−5.4%
Q3 2024Nov 13, 2024 · Before open+11.2%
Q2 2024Aug 13, 2024 · After close+8.6%
All 20 quarters
QuarterResultsShare move
Q1 2024May 13, 2024 · After close−1.1%
Q4 2023Mar 26, 2024 · After close−1.6%
Q3 2023Nov 13, 2023 · After close−6.3%
Q2 2023Aug 14, 2023 · After close−10.7%
Q1 2023May 15, 2023 · After close−10.0%
Q4 2022Mar 31, 2023 · After close−8.0%
Q3 2022Nov 14, 2022 · After close−0.6%
Q2 2022Aug 10, 2022+3.6%
Q1 2022May 19, 2022+14.3%
Q4 2021Mar 10, 2022−3.9%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (November 2026)Investor deck35 slidesNov 16, 2026
Investor Presentation (November 2026)Investor deck29 slidesNovember 2026
Investor Presentation (October 2026)Investor deck28 slidesOctober 2026
Investor Presentation (August 2026)Investor deck29 slidesAug 17, 2026
Investor Presentation (July 2026)Investor deck18 slidesJul 16, 2026
Investor Presentation (June 2026)Investor deck28 slidesJun 4, 2026
Corporate Update (November 2025)Corporate update26 slidesNov 13, 2025
Investor Presentation (September 2025)Investor deck26 slidesSep 9, 2025
Q2 2025 Earnings PresentationEarnings35 slidesAug 13, 2025
Investor Presentation (June 2025)Investor deck39 slidesJun 17, 2025
All 44 decks
DeckKindSlidesDate
Investor Presentation (March 2025)Investor deck36 slidesMar 31, 2025
Q3 2024 Earnings PresentationEarnings33 slidesNov 13, 2024
Q2 2024 Earnings PresentationEarnings33 slidesAug 13, 2024
Investor Presentation (May 2024)Investor deck34 slidesMay 13, 2024
Investor Presentation (March 2024)Investor deck34 slidesMar 26, 2024
Investor Presentation (February 2024)Investor deck34 slidesFeb 28, 2024
Q3 2023 Earnings PresentationEarnings33 slidesNov 14, 2023
Investor Presentation (September 2023)Investor deck27 slidesSep 18, 2023
Investor Presentation (August 2023)Investor deck27 slidesAug 29, 2023
Q1 2023 Earnings PresentationEarnings27 slidesMay 15, 2023
Investor Presentation (March 2023)Investor deck27 slidesMar 21, 2023
Investor Presentation (February 2023)Investor deck28 slidesFeb 17, 2023
Investor Presentation (January 2023)Investor deck28 slidesJan 6, 2023
Investor Presentation (October 2022)Investor deck27 slidesOct 17, 2022
Investor Presentation (September 2022)Investor deck26 slidesSep 23, 2022
Second Sight Medical Products — Merger or Acquisition (February 2022)Merger or acquisition25 slidesFeb 8, 2022
Second Sight Medical Products — Merger or Acquisition (January 2021)Merger or acquisition36 slidesJan 6, 2021
Second Sight Medical Products — IPO Roadshow (April 2020)IPO roadshow14 slidesApr 29, 2020
Second Sight Medical Products — 2019 Wells Fargo Healthcare ConferenceConference16 slidesSep 4, 2019
Second Sight Medical Products — Technical Presentation (June 2019)Technical28 slidesJun 25, 2019
Second Sight Medical Products — B. Riley FBR Investor Conference 2019Conference15 slidesMay 23, 2019
Second Sight Medical Products — Technical Presentation (April 2019)Technical4 slidesApr 11, 2019
Second Sight Medical Products — Technical Presentation (April 2019)Technical20 slidesApr 11, 2019
Second Sight Medical Products — Digital Medicine and Medtech Showcase (January 2019)Conference14 slidesJan 9, 2019
Second Sight Medical Products — LD Micro Main Event 2018Conference15 slidesDec 5, 2018
Second Sight Medical Products — Investor Presentation (September 2018)Investor deck14 slidesSep 4, 2018
Second Sight Medical Products — Investor Presentation (May 2018)Investor deck12 slidesMay 24, 2018
Second Sight Medical Products — Investor Presentation (March 2018)Investor deck17 slidesMar 7, 2018
Second Sight Medical Products — Investor Presentation (September 2017)Investor deck23 slidesSep 12, 2017
Second Sight Medical Products — Investor Presentation (May 2017)Investor deck19 slidesMay 25, 2017
Second Sight Medical Products — Technical Presentation (February 2016)Technical18 slidesFeb 26, 2016
Second Sight Medical Products — Investor Presentation (February 2016)Investor deck19 slidesFeb 23, 2016
Second Sight Medical Products — Investor Presentation (June 2015)Investor deck23 slidesJun 4, 2015
Second Sight Medical Products — Investor Presentation (January 2015)Investor deck23 slidesJan 13, 2015

Open Decks

Financings

RaiseDate
Private placement of common stock
Announced: about US$5.1M · US$1.01 a share
Buyers: Gregg Williams; Aaron Mendelsohn
Insiders: Purchased by Chairman Gregg Williams and director Aaron Mendelsohn
Use of proceeds: Research and clinical development of NPM-139 semaglutide implant and other candidates, working capital and general corporate purposes
Nov 16, 2026
Registered direct offering of shares of common stock
Closed: US$1.48 a share · ThinkEquity
Dealers: ThinkEquity (lead)
Use of proceeds: Research and clinical development of product candidates, working capital and general corporate purposes
Jan 27, 2026
Private placement of shares of common stock
Closed: US$1.48 a share
Buyers: Gregg Williams (1,351,351 shares of common stock at $1.48 per share)
Insiders: All shares purchased by Gregg Williams, Chairman of the board
Use of proceeds: Research and clinical development of product candidates, working capital and general corporate purposes
Jan 27, 2026
Private placement of shares of common stock
Announced: about US$10M · US$1.26 a share
Buyers: entity beneficially owned by Gregg Williams
Insiders: Two investors including an entity beneficially owned by Chairman Gregg Williams
Use of proceeds: Secure financial position into second half of 2026 and accelerate development of NPM-139 into clinical-stage development
Aug 13, 2025
Private placement of shares
Update: about US$3M · US$1.03 a share
May 13, 2025
Private placement of shares
Announced: about US$8.25M · US$1.12 a share
Buyers: Entity beneficially owned by Gregg Williams
Insiders: The Company has entered into a securities purchase agreement with an entity beneficially owned by Gregg Williams, the Chairman of the board
Use of proceeds: Extend cash runway into Q2 2026; accelerate development of NPM-139 semaglutide implant and continue development of NPM-115
Mar 27, 2025

Open Financings · Read by 6ix AI from the company's releases

IPO

Went public as SECOND SIGHT MEDICAL PRODUCTS INC. Priced at US$9.00 a share on Nov 18, 2014.

Price
US$9.00 a share
Shares offered
3,500,000 shares of common stock
Offering size
US$31.5 million
Listing
EYES on the Nasdaq Capital Market
Underwriter
MDB Capital Group, LLC
Shares delivered
On or about Nov 24, 2014

Steps

StepWhen
Filed publiclyAug 12, 2014
Amended 3 timesNewest Nov 14, 2014
Shares registered with an exchangeNov 14, 2014
Declared effective by the SECNov 18, 2014
Final prospectus, with the priceNov 20, 2014

Open IPO · From the cover of the final prospectus (424B3) filed Nov 20, 2014

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue00002601.00K3.38M6.90M7.96M4.00M
Cost of revenue424.0K400.0K357.0K381.0K130.0K500.0K2.15M4.89M5.12M10.1M
Gross profit-424.0K-400.0K-357.0K-381.0K130.0K500.0K1.23M2.01M2.85M-6.09M
Research and development18.1M15.7M17.0M14.2M11.0M4.84M13.1M10.0M7.89M5.35M
Selling, general and administrative9.43M8.93M10.00M5.37M2.32M2.38M9.23M10.7M10.9M10.1M
Operating income-27.6M-24.7M-27.0M-21.2M-13.3M-14.9M-34.0M-35.2M-28.6M-33.2M
Depreciation and amortization424.0K400.0K357.0K381.0K345.0K164.0K397.0K435.0K457.0K432.0K
EBITDA-27.1M-24.3M-26.6M-20.9M-13.0M-14.7M-33.6M-34.7M-28.2M-32.8M
Interest expense7.35M550.0K000
Income before tax-26.6M-23.5M-25.7M-13.9M-12.8M-9.28M-33.6M-35.1M-28.5M-33.2M
Income tax2.00K-7.35M-641.0K147.7K0093.0K31.0K
Net income-26.6M-23.5M-25.7M-13.9M-12.8M-14.9M-33.6M-35.1M-28.5M-33.2M
Earnings per share, basic-0.43-0.43-0.50-273.75-0.27-0.72-2.28-4.23-0.53-0.84
Earnings per share, diluted-0.43-0.43-0.50-0.27-0.72-2.28-4.23-0.53-0.84

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents16.2M18.4M20.7M45.1M2.18M2.08M11.3M4.47M7.84M10.9M
Short-term investments7.24M10.3M
Receivables654.0K253.0K455.0K504.0K1.83M274.0K
Inventory1.03M3.25M2.70M3.42M
Current assets17.9M20.4M23.1M47.5M2.47M4.27M13.1M9.62M13.2M15.3M
Property, plant and equipment2.88M1.69M1.73M1.18M1.17M174.0K1.12M1.02M1.30M1.49M
Total assets39.4M41.6M45.8M51.1M5.45M4.46M16.6M10.7M14.5M16.8M
Accounts payable1.03M817.0K542.0K1.18M281.0K486.0K1.09M1.30M752.0K1.16M
Current liabilities6.60M5.99M5.72M6.82M2.09M5.13M6.96M7.60M6.62M5.66M
Total debt18.9M19.3M20.7M955.0K1.81M2.47M2.60M
Total liabilities23.7M24.0M25.0M6.82M2.99M5.13M9.32M7.60M6.62M5.66M
Shareholders' equity15.7M17.6M20.8M44.3M2.46M1.95M7.28M3.08M7.88M11.1M
Shares outstanding76.4M59.2M51.0M50.7K36.8M23.2K15.6M9.54M57.6M42.7M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-24.3M-20.8M-23.7M-18.8M-11.0M-16.8M-27.6M-29.8M-23.9M-25.1M
Capital spending-1.17M-556.0K-887.0K-338.0K-572.0K-330.0K-493.0K-163.0K-265.0K-490.0K
Free cash flow-25.5M-21.3M-24.6M-19.1M-11.5M-17.2M-28.1M-30.0M-24.2M-25.6M
Cash from investing-1.17M-556.0K-887.0K-338.0K-572.0K68.0K-493.0K-163.0K-265.0K-490.0K
Cash from financing23.3M19.1M133.0K63.4M11.6M8.60M35.0M26.6M21.2M20.5M
Share buybacks-28.0K-281.0K
Change in cash-2.12M-2.30M-24.4M44.3M97.0K-8.15M6.86M-3.37M-3.04M-5.08M

Open Financials

Filings

FilingDateTypeFiled with
4/A · Change in ownership, amendedNov 20, 2026Insider tradeSEC
4 · Change in ownershipNov 20, 2026Insider tradeSEC
4 · Change in ownershipNov 19, 2026Insider tradeSEC
4 · Change in ownershipNov 18, 2026Insider tradeSEC
8-K · Current reportNov 16, 2026Material contractSEC
4 · Change in ownershipNov 16, 2026Insider tradeSEC
4 · Change in ownershipNov 13, 2026Insider tradeSEC
8-K · Current reportNov 12, 2026ResultsSEC
10-Q · Quarterly reportNov 12, 2026Quarterly reportSEC
8-K · Current reportOct 30, 2026Current reportSEC
Show 200 filings
FilingDateTypeFiled with
8-K · Current reportOct 29, 2026Current reportSEC
4 · Change in ownershipOct 19, 2026Insider tradeSEC
424B5 · ProspectusSep 25, 2026Offer documentSEC
8-K · Current reportSep 16, 2026Current reportSEC
8-K · Current reportAug 17, 2026Current reportSEC
8-K · Current reportAug 13, 2026ResultsSEC
10-Q · Quarterly reportAug 13, 2026Quarterly reportSEC
8-K · Current reportAug 6, 2026Current reportSEC
4 · Change in ownershipJul 30, 2026Insider tradeSEC
4 · Change in ownershipJul 30, 2026Insider tradeSEC
4 · Change in ownershipJul 30, 2026Insider tradeSEC
4 · Change in ownershipJul 30, 2026Insider tradeSEC
4 · Change in ownershipJul 30, 2026Insider tradeSEC
4 · Change in ownershipJul 28, 2026Insider tradeSEC
4 · Change in ownershipJul 16, 2026Insider tradeSEC
8-K · Current reportJul 16, 2026Current reportSEC
8-K · Current reportJul 7, 2026Material contractSEC
8-K · Current reportJun 30, 2026Management or board changeSEC
4 · Change in ownershipJun 26, 2026Insider tradeSEC
3 · Initial statement of ownershipJun 26, 2026Insider tradeSEC
4 · Change in ownershipJun 25, 2026Insider tradeSEC
4 · Change in ownershipJun 25, 2026Insider tradeSEC
4 · Change in ownershipJun 25, 2026Insider tradeSEC
4 · Change in ownershipJun 25, 2026Insider tradeSEC
4 · Change in ownershipJun 16, 2026Insider tradeSEC
8-K · Current reportJun 4, 2026Current reportSEC
SCHEDULE 13D/A · Big-stake notice, amendedMay 19, 2026Big-stake noticeSEC
4 · Change in ownershipMay 19, 2026Insider tradeSEC
8-K · Current reportMay 13, 2026ResultsSEC
10-Q · Quarterly reportMay 13, 2026Quarterly reportSEC
ARS · Annual report to shareholdersApr 29, 2026Annual reportSEC
DEFA14A · Additional proxy materialApr 29, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 29, 2026Meeting noticeSEC
4 · Change in ownershipApr 16, 2026Insider tradeSEC
8-K · Current reportMar 26, 2026ResultsSEC
10-K · Annual reportMar 26, 2026Annual reportSEC
4 · Change in ownershipMar 16, 2026Insider tradeSEC
4 · Change in ownershipFeb 17, 2026Insider tradeSEC
4 · Change in ownershipJan 28, 2026Insider tradeSEC
8-K · Current reportJan 27, 2026Material contractSEC
424B5 · ProspectusJan 27, 2026Offer documentSEC
4 · Change in ownershipJan 20, 2026Insider tradeSEC
4 · Change in ownershipJan 5, 2026Insider tradeSEC
4 · Change in ownershipJan 5, 2026Insider tradeSEC
4 · Change in ownershipDec 31, 2025Insider tradeSEC
4 · Change in ownershipDec 16, 2025Insider tradeSEC
4 · Change in ownershipNov 17, 2025Insider tradeSEC
10-Q · Quarterly reportNov 13, 2025Quarterly reportSEC
8-K · Current reportNov 13, 2025ResultsSEC
4 · Change in ownershipOct 28, 2025Insider tradeSEC
8-K · Current reportOct 28, 2025Material contractSEC
424B5 · ProspectusOct 27, 2025Offer documentSEC
4 · Change in ownershipOct 16, 2025Insider tradeSEC
8-K · Current reportOct 3, 2025Current reportSEC
4 · Change in ownershipSep 17, 2025Insider tradeSEC
8-K · Current reportSep 17, 2025Current reportSEC
8-K · Current reportSep 9, 2025Current reportSEC
8-K · Current reportSep 4, 2025Current reportSEC
10-Q · Quarterly reportAug 13, 2025Quarterly reportSEC
8-K · Current reportAug 13, 2025ResultsSEC
8-K · Current reportAug 5, 2025ResultsSEC
4 · Change in ownershipJun 26, 2025Insider tradeSEC
4 · Change in ownershipJun 26, 2025Insider tradeSEC
4 · Change in ownershipJun 26, 2025Insider tradeSEC
4 · Change in ownershipJun 26, 2025Insider tradeSEC
4 · Change in ownershipJun 26, 2025Insider tradeSEC
8-K · Current reportJun 25, 2025Meeting outcomeSEC
4 · Change in ownershipJun 17, 2025Insider tradeSEC
3 · Initial statement of ownershipJun 17, 2025Insider tradeSEC
8-K · Current reportJun 17, 2025Current reportSEC
8-K · Current reportJun 11, 2025Management or board changeSEC
8-K · Current reportMay 29, 2025Current reportSEC
4 · Change in ownershipMay 16, 2025Insider tradeSEC
4 · Change in ownershipMay 14, 2025Insider tradeSEC
4 · Change in ownershipMay 14, 2025Insider tradeSEC
4 · Change in ownershipMay 14, 2025Insider tradeSEC
4 · Change in ownershipMay 14, 2025Insider tradeSEC
4 · Change in ownershipMay 14, 2025Insider tradeSEC
10-Q · Quarterly reportMay 13, 2025Quarterly reportSEC
8-K · Current reportMay 13, 2025ResultsSEC
DEFR14AMay 6, 2025Meeting noticeSEC
ARS · Annual report to shareholdersApr 29, 2025Annual reportSEC
DEFA14A · Additional proxy materialApr 29, 2025Meeting noticeSEC
DEF 14A · Proxy statementApr 29, 2025Meeting noticeSEC
4 · Change in ownershipApr 28, 2025Insider tradeSEC
4 · Change in ownershipApr 23, 2025Insider tradeSEC
8-K · Current reportApr 15, 2025Current reportSEC
4 · Change in ownershipApr 11, 2025Insider tradeSEC
4 · Change in ownershipApr 8, 2025Insider tradeSEC
4 · Change in ownershipApr 4, 2025Insider tradeSEC
4 · Change in ownershipApr 1, 2025Insider tradeSEC
10-K · Annual reportMar 31, 2025Annual reportSEC
8-K · Current reportMar 31, 2025ResultsSEC
8-K · Current reportMar 27, 2025Material contractSEC
8-K · Current reportMar 26, 2025Current reportSEC
8-K · Current reportMar 13, 2025ResultsSEC
4 · Change in ownershipMar 3, 2025Insider tradeSEC
4 · Change in ownershipJan 3, 2025Insider tradeSEC
4 · Change in ownershipJan 3, 2025Insider tradeSEC
4 · Change in ownershipNov 13, 2024Insider tradeSEC
10-Q · Quarterly reportNov 13, 2024Quarterly reportSEC
8-K · Current reportNov 13, 2024ResultsSEC
8-K · Current reportOct 22, 2024Current reportSEC
4 · Change in ownershipOct 3, 2024Insider tradeSEC
8-K · Current reportSep 26, 2024Current reportSEC
8-K · Current reportSep 23, 2024Current reportSEC
8-K · Current reportSep 4, 2024Current reportSEC
8-K · Current reportAug 13, 2024ResultsSEC
10-Q · Quarterly reportAug 13, 2024Quarterly reportSEC
4 · Change in ownershipAug 1, 2024Insider tradeSEC
4 · Change in ownershipAug 1, 2024Insider tradeSEC
8-K · Current reportJul 11, 2024Current reportSEC
4 · Change in ownershipJul 1, 2024Insider tradeSEC
4 · Change in ownershipJul 1, 2024Insider tradeSEC
4 · Change in ownershipJul 1, 2024Insider tradeSEC
4 · Change in ownershipJul 1, 2024Insider tradeSEC
4 · Change in ownershipJul 1, 2024Insider tradeSEC
8-K · Current reportJun 28, 2024Meeting outcomeSEC
8-K · Current reportJun 13, 2024Current reportSEC
4 · Change in ownershipMay 14, 2024Insider tradeSEC
4 · Change in ownershipMay 14, 2024Insider tradeSEC
4 · Change in ownershipMay 14, 2024Insider tradeSEC
4 · Change in ownershipMay 14, 2024Insider tradeSEC
4 · Change in ownershipMay 14, 2024Insider tradeSEC
10-Q · Quarterly reportMay 13, 2024Quarterly reportSEC
8-K · Current reportMay 13, 2024ResultsSEC
EFFECT · Notice that a registration is effectiveMay 6, 2024Other filingsSEC
CORRESP · Letter to the SECMay 2, 2024Other filingsSEC
S-3/A · Registration statement, amendedMay 2, 2024Offer documentSEC
ARS · Annual report to shareholdersApr 29, 2024Annual reportSEC
DEFA14A · Additional proxy materialApr 29, 2024Meeting noticeSEC
DEF 14A · Proxy statementApr 29, 2024Meeting noticeSEC
UPLOAD · Letter from the SECApr 29, 2024Other filingsSEC
8-K · Current reportApr 22, 2024Material contractSEC
S-3 · Registration statementApr 22, 2024Offer documentSEC
4 · Change in ownershipMar 29, 2024Insider tradeSEC
4 · Change in ownershipMar 27, 2024Insider tradeSEC
10-K · Annual reportMar 26, 2024Annual reportSEC
8-K · Current reportMar 26, 2024ResultsSEC
3 · Initial statement of ownershipMar 11, 2024Insider tradeSEC
8-K · Current reportMar 6, 2024Management or board changeSEC
8-K · Current reportMar 5, 2024Material contractSEC
424B5 · ProspectusMar 5, 2024Offer documentSEC
144 · Notice of proposed saleMar 5, 2024Other filingsSEC
8-K · Current reportFeb 28, 2024Current reportSEC
4 · Change in ownershipFeb 20, 2024Insider tradeSEC
4 · Change in ownershipFeb 9, 2024Insider tradeSEC
4 · Change in ownershipFeb 6, 2024Insider tradeSEC
4 · Change in ownershipFeb 2, 2024Insider tradeSEC
4 · Change in ownershipJan 25, 2024Insider tradeSEC
4 · Change in ownershipJan 22, 2024Insider tradeSEC
4 · Change in ownershipJan 19, 2024Insider tradeSEC
4 · Change in ownershipJan 16, 2024Insider tradeSEC
8-K · Current reportJan 10, 2024Current reportSEC
4 · Change in ownershipJan 9, 2024Insider tradeSEC
4 · Change in ownershipJan 5, 2024Insider tradeSEC
4 · Change in ownershipJan 3, 2024Insider tradeSEC
4 · Change in ownershipDec 27, 2023Insider tradeSEC
8-K · Current reportDec 27, 2023Current reportSEC
4 · Change in ownershipDec 21, 2023Insider tradeSEC
4 · Change in ownershipDec 18, 2023Insider tradeSEC
4 · Change in ownershipDec 18, 2023Insider tradeSEC
4 · Change in ownershipDec 13, 2023Insider tradeSEC
4 · Change in ownershipDec 8, 2023Insider tradeSEC
4 · Change in ownershipNov 27, 2023Insider tradeSEC
8-K · Current reportNov 24, 2023Management or board changeSEC
4 · Change in ownershipNov 22, 2023Insider tradeSEC
4 · Change in ownershipNov 20, 2023Insider tradeSEC
8-K · Current reportNov 14, 2023ResultsSEC
10-Q · Quarterly reportNov 13, 2023Quarterly reportSEC
4 · Change in ownershipOct 24, 2023Insider tradeSEC
4 · Change in ownershipOct 16, 2023Insider tradeSEC
4 · Change in ownershipOct 11, 2023Insider tradeSEC
4 · Change in ownershipOct 10, 2023Insider tradeSEC
4 · Change in ownershipOct 5, 2023Insider tradeSEC
4 · Change in ownershipOct 2, 2023Insider tradeSEC
4 · Change in ownershipSep 27, 2023Insider tradeSEC
4 · Change in ownershipSep 27, 2023Insider tradeSEC
4 · Change in ownershipSep 22, 2023Insider tradeSEC
4 · Change in ownershipSep 18, 2023Insider tradeSEC
8-K · Current reportSep 18, 2023Current reportSEC
4 · Change in ownershipSep 12, 2023Insider tradeSEC
4 · Change in ownershipSep 7, 2023Insider tradeSEC
4 · Change in ownershipSep 5, 2023Insider tradeSEC
4 · Change in ownershipSep 5, 2023Insider tradeSEC
4 · Change in ownershipSep 1, 2023Insider tradeSEC
8-K · Current reportAug 28, 2023Material contractSEC
4 · Change in ownershipAug 18, 2023Insider tradeSEC
10-Q · Quarterly reportAug 14, 2023Quarterly reportSEC
8-K · Current reportJul 10, 2023Current reportSEC

This page holds 200 of 847 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Vivani Medical, Inc.’s releases · as of Nov 16, 2026

Common shares
90,203,356
Fully diluted
90,203,356

Fully diluted

LineSharesAs of
Common shares90,203,356Nov 12, 2026

Share count over time

CountShares
Nov 12, 202690,203,356

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Vanguard1.69M1.9%US$2.09MSep 30, 2026
Tanager Wealth Management LLP607K0.67%US$753KSep 30, 2026
Geode Capital519K0.57%US$643KSep 30, 2026
Commonwealth Equity Services, LLC321K0.36%US$398KSep 30, 2026
BlackRock293K0.33%US$364KSep 30, 2026
Monetary Management Group Inc194K0.22%US$241KSep 30, 2026
Susquehanna156K0.17%US$193KSep 30, 2026
State Street155K0.17%US$192KSep 30, 2026
Jane Street122K0.14%US$152KSep 30, 2026
Northern Trust117K0.13%US$145KSep 30, 2026
All 36 holders
HolderSharesOf the companyValueAs of
Arax Advisory Partners100K0.11%US$124KSep 30, 2026
MAI Capital Management99,8700.11%US$124KSep 30, 2026
Millennium70,7300.08%US$87,705Sep 30, 2026
Citadel54,7580.06%US$67,900Sep 30, 2026
Gsa Capital Partners LLP54,1460.06%US$67,000Sep 30, 2026
Armstrong Advisory Group, Inc25,0000.03%US$31,000Sep 30, 2026
Schonfeld Strategic Advisors LLC19,0000.02%US$23,560Sep 30, 2026
Focus Partners Wealth16,1440.02%US$20,019Sep 30, 2026
StoneX Group Inc.15,3690.02%US$20,059Sep 30, 2026
Marshall Wace, LLP11,1610.01%US$13,839Sep 30, 2026
Lazari Capital Management, Inc.10,0000.01%US$12,400Sep 30, 2026
Simplex Trading, LLC3,787<0.01%US$4,695Sep 30, 2026
Steward Partners Investment Advisory, LLC2,000<0.01%US$2,480Sep 30, 2026
JPMorgan1,662<0.01%US$2,044Sep 30, 2026
Jones Financial Companies Lllp1,200<0.01%US$1,488Sep 30, 2026
SBI Securities Co., Ltd.1,165<0.01%US$1,445Sep 30, 2026
Rothschild Investment LLC1,000<0.01%US$1,240Sep 30, 2026
Pinnacle Financial Group, Inc.796<0.01%US$988Sep 30, 2026
Osaic Holdings, Inc.220<0.01%US$272Sep 30, 2026
UBS202<0.01%US$250Sep 30, 2026
NFSG Corp103<0.01%US$128Sep 30, 2026
Highland Investment Advisors LLC32<0.01%US$40Sep 30, 2026
Caitong International Asset Management Co., Ltd13<0.01%US$16Sep 30, 2026
Barclays11<0.01%US$14Sep 30, 2026
Morgan Stanley1<0.01%US$1Sep 30, 2026
Danske Bank A/S1<0.01%US$1Sep 30, 2026

Funds

HolderSharesOf the companyValueAs of
Vanguard Total Stock Market Index Fund1.11M1.2%US$1.38MJun 30, 2026
Vanguard Extended Market Index Fund644K0.71%US$798KJun 30, 2026
Fidelity Extended Market Index Fund284K0.31%US$375KMay 31, 2026
iShares Micro-Cap ETF134K0.15%US$166KJun 30, 2026
Fidelity Series Total Market Index Fund69,6790.08%US$91,976May 31, 2026
Fidelity Total Market Index Fund58,5670.06%US$77,308May 31, 2026
Fidelity Nasdaq Composite Index Fund47,6260.05%US$62,866May 31, 2026
Vanguard Balanced Index Fund13,2440.01%US$16,423Jun 30, 2026
1290 VT Micro Cap Portfolio8,403<0.01%US$10,420Jun 30, 2026
Victory Extended Market Index Fund4,637<0.01%US$5,935Jul 31, 2026

Insider trades

TradeTradeSharesPriceValueDate
Williams Gregg
Director, 10% owner
Buy85,265USD 1.09US$93,365Nov 19, 2026
Williams Gregg
Director, 10% owner
Buy33,169USD 1.05US$34,960Nov 18, 2026
Williams Gregg
Director, 10% owner
Buy29,929USD 1.05US$31,455Nov 17, 2026
Williams Gregg
Director, 10% owner
Buy2,100USD 1.01US$2,121Nov 16, 2026
Williams Gregg
Director, 10% owner
Buy48,100USD 0.99US$47,763Nov 13, 2026
Dwyer Donald
Officer: Chief Business Officer
Buy5,000USD 0.83US$4,150Nov 12, 2026
Dwyer Donald
Officer: Chief Business Officer
Buy15,000USD 1.03US$15,495Nov 12, 2026
Williams Gregg
Director, 10% owner
Buy793,650USD 1.26US$1000KJul 15, 2026
Williams Gregg
Director, 10% owner
Buy1,587,301USD 1.26US$2MJun 15, 2026
Williams Gregg
Director, 10% owner
Buy1,587,301USD 1.26US$2MMay 15, 2026
All 11 trades
TradeTradeSharesPriceValueDate
Williams Gregg
Director, 10% owner
Buy1,587,301USD 1.26US$2MApr 15, 2026

Big stakes

StakeStakeSharesDateFiling
Williams Gregg47.10%43.2MMay 15, 2026Schedule 13D

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
William J. Link
Other companies: RxSight, Inc. (Director · Since at least Jul 29, 2021); Tarsus Pharmaceuticals, Inc. (Director · Since at least Oct 15, 2020); LENSAR, Inc. (Director · Since at least Sep 17, 2020); Oyster Point Pharma Inc (Director · Oct 30, 2019 – Jan 5, 2022 · Past); Glaukos Corporation (Director · Jun 24, 2015 – Jun 3, 2021 · Past); Flexion Therapeutics Inc (Director · Sep 10, 2014 – Sep 10, 2014 · Past); Inogen, Inc (Director · Feb 12, 2014 – Feb 20, 2014 · Past); Edwards Lifesciences Corporation (Director · May 15, 2013 – May 8, 2020 · Past)
Director · Nov 18, 2014 – Jun 4, 2019 · Past
Brigid A. Makes
Other companies: Elutia, Inc. (Board Member · Since at least May 29, 2025); Quantum-Si Incorporated (Director · Since at least May 19, 2025)
Chief Financial Officer · May 12, 2025 – May 12, 2025 · Past
Aaron MendelsohnMember of the Board · Since at least Oct 19, 2026
Adam MendelsohnCo-Founder & Chief Executive Officer · Since at least Oct 12, 2026
Alexandra L. PopoffMember of the Board · Since at least Nov 5, 2026
Anne-Marie Juliette RipleyVP of Regulatory Affairs · Nov 18, 2014 – Dec 4, 2015 · Past
Anthony BaldorChief Financial Officer · Since at least Jun 11, 2025
August J. MorettiMember of the Board · Since at least Jun 26, 2026
Daniel BradburyMember of the Board · Since at least Nov 5, 2026
Donald DwyerChief Business Officer · Since at least Oct 12, 2026
All 20 people
PersonSeat
Gregg WilliamsDirector · Since at least May 18, 2022
Gregoire CosendaiVP Clinical Affairs · Nov 18, 2014 – Jan 4, 2018 · Past
Jami TaylorInvestor Relations · Since at least Jan 29, 2026
John Anthony MosesCommercial VP Americas · May 25, 2015 – Jan 21, 2016 · Past
Lisa PorterChief Medical Officer · Since at least Apr 16, 2025
Matthew J PfefferDirector · Jun 1, 2018 – Jun 4, 2019 · Past
Stephen D OklandChief Commercial Officer · Mar 28, 2016 – Feb 19, 2019 · Past
Thomas B MillerChief Financial Officer · Jan 21, 2016 – Jan 19, 2018 · Past
Truc LeChief Operations Officer · Since at least Aug 30, 2022
Wilford Dean BakerDirector · Since at least Apr 6, 2021

Open People

Log in to ask 6ix AI your own questions about Vivani Medical, Inc.